OR WAIT null SECS
September 01, 2021
The European Commission has granted marketing authorization to Incyte and MorphoSys for Minjuvi (tafasitamab) in combination therapy with lenalidomide to treat relapsed or refractory DLBCL.
SpringWorks Therapeutics and the Dana-Farber Cancer Institute will conduct further research into the therapeutic potential of combination therapy with nirogacestat and anti-BCMA agents for multiple myeloma.
Aadi Bioscience has closed its previously announced merger with Aerpio Pharmaceuticals and a concurrent $155-million PIPE investment.
Quotient Sciences is investing £6.3 million ($8.68 million) into their drug substance manufacturing capabilities.
Avantor plans to address rising global demand for biologics with their investment in hydration capabilities.
August 31, 2021
Catalent’s acquisition of Bettera paves the way for growth in the softgel and oral dose formulation and manufacturing market for nutraceuticals.
USAntibiotics will serve as the sole American-based provider of amoxicillin and amoxil clavulanate.
FDA formally unveiled its plan for revising and renewing its fee program for drugs and biologics.
August 30, 2021
After receiving the COVID-19 vaccine from a batch of Moderna vaccines that were suspected to have contaminants, two people in Japan died. Meanwhile, another one million doses have been temporarily suspended in Japan.
August 27, 2021
The IPEC Foundation announced its 2021 award winners, who will be honored at their annual award ceremony in Philadelphia.